Abstract
A murine monoclonal antibody, m357, showing the highly neutralizing activities for human tumor necrosis factor (TNF-α) was chosen to be humanized by a variable domain resurfacing approach. The non-conserved surface residues in the framework regions of both the heavy and light chain variable regions were identified via a molecular modeling of m357 built by computer-assisted homology modeling. By replacing these critical surface residues with the human counterparts, a humanized version, h357, was generated. The humanized h357 IgG 1 was then stably expressed in a mammalian cell line and the purified antibody maintained the high antigen binding affinity as compared with the parental m357 based on a soluble TNF-α neutralization bioassay. Furthermore, h357 IgG 1 possesses the ability to mediate antibody-dependent cell-mediated cytotoxicity and complement dependent cytotoxicity upon binding to cells bearing the transmembrane form of TNF-α. In a mouse model of collagen antibody-induced arthritis, h357 IgG significantly inhibited disease progression by intra-peritoneal injection of 50 mg/mouse once-daily for 9 consecutive days. These results provided a basis for the development of h357 IgG as therapeutic use. © 2011 Chiu et al.
Cite
CITATION STYLE
Chiu, W. C., Lai, Y. P., & Chou, M. Y. (2011). Humanization and Characterization of an anti-human TNF-α murine monoclonal antibody. PLoS ONE, 6(1). https://doi.org/10.1371/journal.pone.0016373
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.